Heterodimeric antibodies that bind to CD3 and tumor antigens
Heterodimeric antibodies with monovalent binding to CD3 and CD38 address biophysical and pharmacokinetic barriers, improving therapeutic efficacy by avoiding nonspecific activation and enhancing treatment of hematopoietic malignancies.
Patent Information
- Application Number
- JP2020073781
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2015-11-25
- Filing Date
- 2020-04-17
- Publication Date
- 2025-11-06
- Estimated Expiration
- 2036-04-28
AI Technical Summary
Existing bispecific antibodies face biophysical and pharmacokinetic barriers, and multivalent association with co-target antigens leads to nonspecific activation and potential toxicity, limiting their clinical efficacy in treating cancers like non-Hodgkin's lymphoma and leukemia.
Development of heterodimeric antibodies with monovalent binding to CD3 and CD38, utilizing a novel format that includes a first and second monomer with specific variable and constant domains, linked by domain linkers, to create a bispecific antibody that avoids bivalent cross-linking and reduces toxicity.
The heterodimeric antibodies effectively target CD3 and CD38, enhancing therapeutic efficacy by reducing nonspecific activation and improving pharmacokinetic properties, making them suitable for treating hematopoietic malignancies such as non-Hodgkin's lymphoma and leukemia.